Pegylated Interferon Alfa-2a Salvage Therapy in High Risk Polycythemia Vera (PV) or Essential Thrombocythemia (ET)

PHASE2CompletedINTERVENTIONAL
Enrollment

135

Participants

Timeline

Start Date

September 30, 2011

Primary Completion Date

December 31, 2016

Study Completion Date

December 31, 2016

Conditions
High Risk Polycythemia VeraHigh Risk Essential Thrombocythemia
Interventions
DRUG

PEGASYS

Patient will start at 45 micrograms per week and gradually increase to 180 micrograms per week. Pegasys will be supplied in prefilled syringes and are to be given subcutaneously.

DRUG

Aspirin

81 or 100 mg daily.

Trial Locations (21)

10029

Icahn School of Medicine at Mount Sinai, New York

10065

Memorial Sloan-Kettering Cancer Center, New York

Weill Cornell Medical College, New York

11632

Ospedale San Maartino Genova, Genova

17822

Geisinger Cancer Center, Danville

19104

University of Pennsylvania, Philadelphia

20007

Georgetown University Medical Center, Washington D.C.

21201

University of Maryland, Baltimore

27100

San Matteo Hospital, Pavia

27157

Wake Forest University Baptist Medical Center, Winston-Salem

27710

Duke University Medical Center, Durham

30322

Emory Hospital, Atlanta

60612

John H. Stroger Hospital of Cook County, Chicago

University of Illinois at Chicago, Chicago

66205

University of Kansas Cancer Center, Westwood

84132

University of Utah, Salt Lake City

85259

Mayo Clinic, Scottsdale

94301

The Palo Alto Clinic, Palo Alto

Unknown

Ospedale Riuniti de Bergamo, Bergamo

University Of Florence, Florence

Universita Cattolica del Sacro Cuore, Rome

All Listed Sponsors
collaborator

Myeloproliferative Disorders-Research Consortium

NETWORK

collaborator

National Cancer Institute (NCI)

NIH

collaborator

Roche Pharma AG

INDUSTRY

lead

Ronald Hoffman

OTHER

NCT01259817 - Pegylated Interferon Alfa-2a Salvage Therapy in High Risk Polycythemia Vera (PV) or Essential Thrombocythemia (ET) | Biotech Hunter | Biotech Hunter